Compare Amphastar Pharmaceuticals Inc (AMPH) vs Jumia Technologies AG - ADR (JMIA) Price & Performance
Price performance (Past 24H)
Key statistics
Key statistics
Amphastar Pharmaceuticals Inc vs Jumia Technologies AG - ADR — how do they compare? Amphastar Pharmaceuticals Inc trades at $20.39 (market cap $863.95M), while Jumia Technologies AG - ADR trades at $6 (market cap $743.12M). The key difference: Amphastar Pharmaceuticals Inc is the larger of the two by market cap, and Amphastar Pharmaceuticals Inc is trading nearer its 52-week high, Jumia Technologies AG - ADR nearer its low. Which is the better fit depends on your goals.
| AMPH | JMIA | |
|---|---|---|
Market Cap | $863.95M | $743.12M |
Sector | Health | Consumer Cyclical |
52-Week High | $30.81 | $14.60 |
52-Week Low | $16.87 | $5.69 |
Enterprise Value | $1.26B | $690.21M |
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
Aura AI Summary
Signals from Pluang's Aura AI — not financial advice
AMPH trades at $20.78, up 4.9% today, with a bullish technical signal supported by moving averages. The stock shows mixed earnings performance with Q2 2026 beating estimates but Q1 and Q4 2025 missing. Fundamentals remain solid with a 10.76% net margin and reasonable valuation at 12.02 P/E. Recent news highlights Q2 2026 results and strategic shift toward proprietary drugs.
Outlook is cautiously optimistic with growth supported by new product launches, though regulatory risks and earnings volatility pose challenges. Analyst sentiment is mixed with 25% buy ratings but majority hold recommendations. The stock offers value but requires monitoring of FDA developments and earnings consistency.
JMIA trades at $6.19, up 8.79% today, but remains in a bearish technical trend with mixed signals from moving averages and oscillators. Fundamentally, the company shows improving revenue trends ($189M in 2025) and narrowing losses, though it continues to post negative net income margins (-30.79%). Recent news highlights management's focus on achieving profitability by 2027 through strategic partnerships and expansion initiatives.
While analyst consensus remains strongly bullish (71% buy ratings), JMIA faces significant execution risks in its path to profitability. The stock presents speculative upside potential if the company can deliver on its 2027 profitability targets, but investors should weigh the substantial losses against the promising revenue growth trajectory in African e-commerce markets.
Returns comparison
Trailing returns across standard periods
Returns comparison
Trailing returns across standard periods
About Amphastar Pharmaceuticals Inc
Amphastar is a specialty pharmaceutical company that develops and markets injectable, intranasal, and inhalation products. Its portfolio includes both complex generic drugs and proprietary delivery systems.
Read more on AMPH →About Jumia Technologies AG - ADR
Jumia Technologies AG is the pan-African e-commerce platform. The company's platform consists of a marketplace, which connects sellers with consumers. Its logistics service enables the shipment and delivery of packages from sellers to consumers, and the company's payment service facilitates transactions among participants active on its platform in selected markets. Jumia generates revenue from Sales of goods, Commissions, Fulfillment, Value-added services, and Marketing & Advertising. Its geographical segments are West Africa, North Africa, East & South Africa, Europe, and United Arab Emirates. The firm generates most of its revenue from the West Africa segment.
Read more on JMIA →
